All In Biotech

Drug Trial Radar · NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

572

Planned (sponsor's estimate)

Start

Apr 13, 2022

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • Waldenstrom Macroglobulinemia (WM)
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Secondary Central Nervous System Lymphoma (SCNSL)

Interventions

  • NX-5948Drug

    Oral NX-5948

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with protocol specified dose-limiting toxicitiesTime frame: Up to 24 months
  2. To establish the maximum tolerated dose and/or recommended Phase 1b dose(s)Time frame: Up to 24 months
  3. To evaluate the anti-tumor activity of NX-5948 in the dose levels selected for Phase 1b safety expansion based on overall response rate (ORR) as assessed by InvestigatorTime frame: Up to 3 years
  4. Number of participants with treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs), TEAEs leading to study drug discontinuation, deaths due to TEAEs, and all deathsTime frame: Up to 6 years
  5. To further evaluate the anti-tumor activity of NX-5948 in patients with CLL/SLL at the dose identified in Phase 1b Part 1 based on overall response rate (ORR) as assessed by InvestigatorTime frame: Up to 3 years

Locations

62 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • National Institute of Health

    Bethesda, Maryland · Recruiting

  • Cayuga Medical Center

    Ithaca, New York · Withdrawn

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Withdrawn

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • Hôpital Avicenne

    Bobigny, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • CHU Bordeaux

    Pessac, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

  • Institut Curie-Site Saint-Cloud

    Saint-Cloud, France · Recruiting

  • CHRU de Nancy

    Vandœuvre-lès-Nancy, France · Recruiting

  • IRCCS - AOU di Bologna

    Bologna, Italy · Withdrawn

  • ASST Spedali Civili Brescia

    Brescia, Italy · Withdrawn

  • IRCCS Ospedale San Raffaele - Università Vita-Salute San Raffaele di Milano

    Milan, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Rome, Italy · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Withdrawn

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • University Medical Center Utrecht

    Utrecht, Netherlands · Recruiting

  • Medical University of Lublin

    Lublin, Poland · Recruiting

  • AidPort sp. Zo.o

    Skórzewo, Greater Poland Voivodeship, Poland · Recruiting

  • Pratia MCM

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • University Clinical Hostpital in Wroclaw

    Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting

  • Pratia MTZ

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • National Institute of Oncology Warszawa

    Warsaw, Masovian Voivodeship, Poland · Recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.